Logo Université Laval
Logo Université Laval
International Chair on Cardiometabolic Risk
My Healthy Waist
About Us
Our Congress
Recent Contributions
Editorials
My Waistline
Defining CMR
Definition and History
The Obesity and Type 2 Diabetes Epidemics
Epidemiology
Traditional Modifiable CVD Risk Factors
Type 2 Diabetes
Abdominal Obesity vs. CVD: Beyond Body Weight
Abdominal Obesity vs. Type 2 Diabetes: Beyond Body Weight
Visceral Adipose Tissue: the Culprit?
Complications of Visceral Obesity
Causes and Correlates of Visceral Obesity
A Marker of Ectopic Fat Deposition?
Evaluating CMR
Clinical Tools
Imaging Techniques
Assessing CVD Risk: Traditional Approaches
Metabolic Syndrome and Type 2 Diabetes/CVD Risk
Assessing Cardiometabolic Risk
Managing CMR
Targeting Traditional CVD Risk Factors in Patients With Abdominal Obesity
Residual Cardiometabolic Risk of Treated Patients
Effects of Weight Loss on Adipose Tissue Distribution
Managing Cardiometabolic Risk in Abdominally Obese Patients
Preventing Type 2 Diabetes
Documentation Centre
Donate
Documentation centre
Back to results
Key Publications
December 14, 2022
The dawn of a new era of targeted lipid-lowering therapies.
Eur Heart J. 2022;43:3198-3208
Tokgözoğlu L, Libby P
Consult publication
Categories
Cardiovascular Disease
Lipids/Lipoproteins
Prevention
Back to results